24小时热门版块排行榜

返回列表

也到

木虫 (小有名气)

无欲无求

应助: 0 (幼儿园)
金币: 3410.7
散金: 130
红花: 1
帖子: 114
在线: 31.2小时
虫号: 1664466
注册: 2012-03-04
性别: GG
专业: 合成药物化学

[求助] 求linifanib最新临床情况已有1人参与

求linifanib最新临床情况，最好包括临床类型及几期
还有这种药物的发展前景

回复此楼

» 猜你喜欢

» 本主题相关价值贴推荐，对您同样有帮助:

不知所措

1楼 2014-08-19 19:34:32

已阅回复此楼关注TA 给TA发消息送TA红花 TA的回帖

fbifbeaifb

新虫 (初入文坛)

应助: 0 (幼儿园)
金币: 28.3
帖子: 17
在线: 1.7小时
虫号: 3299473
注册: 2014-06-30

这个只能是汤森数据库才能查到了

赞一下

回复此楼

2楼2014-08-20 10:46:28

已阅回复此楼关注TA 给TA发消息送TA红花 TA的回帖

ovk999

金虫 (小有名气)

应助: 14 (小学生)
金币: 948.1
散金: 5
红花: 7
帖子: 145
在线: 103.9小时
虫号: 861578
注册: 2009-10-01
性别: GG
专业: 合成药物化学

【答案】应助回帖

感谢参与，应助指数 +1

AbbVie is developing linifanib, an orally active multi-targeted receptor tyrosine kinase inhibitor, for the treatment of cancer, including non-small cell lung cancer, breast cancer, colorectal cancer, renal cancer and hepatocellular carcinoma. Linifanib was being developed in collaboration with Genentech; however, development later reverted to Abbott. Linifanib acts as both a vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor. It has been shown to stop disease progression by limiting tumour blood-flow. Linifanib is hydrophobic, but is oxidised in the body to A 849529, a hydrophilic metabolite that includes both carboxyl and amino groups. Linifanib is in phase II development for breast, renal, colorectal and non-small cell lung cancer. The compound was being investigated in a phase III trial for hepatocellular carcinoma, but the trial has been terminated.

赞一下

回复此楼